Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab prefilled pen vs prefilled syringe bioavailability study
NCT06946524Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of risankizumab (2 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration at 141 days, Time to Maximum Concentration at 141 days and 5 more. Started May 2025; status: completed.
02
Drugs
risankizumab
Beyond the preview
Go deeper on NCT06946524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946524.